The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.
Brian Huber
Advertisement
Brian Huber is vice-president of Therapeutic Areas, Drug Development, and Consulting at ICON.
Articles by Brian Huber
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
2
Meeting Tomorrow's Market Requirements: Vetter's Perspective on the Future of Fill & Finish
3
Why Drug Shortages Average 5+ Years: PharmTech Explained
4
ADCs, Degraders, Agonists: 4 Deals CMC Teams Should Track
5